Otonomy to Host Pipeline Program Update Conference Call and Webcast
June 08, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy Provides Business Update Related to COVID-19 Pandemic
April 09, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
February 27, 2020 16:15 ET
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30...
Otonomy to Present at Two Upcoming Investor Conferences
February 24, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
February 20, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
January 28, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
January 23, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Provides Corporate and Product Pipeline Update
January 09, 2020 07:30 ET
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) --...
Otonomy to Participate in Two Upcoming Investor Conferences
November 26, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...